SignalChem
Groundbreaking Innovation in Human Recombinant Cell Signaling Products

SignalChem Lifesciences Corporation is a clinicalstage company developing novel targeted therapies for oncology. Its unique business model is built upon four critical pillars of drug discovery and development, bioreagents and research services business, invitro diagnostic products and reagents and plant biosynthesis systems. It creates effective research tools to support scientists in academia, pharma, and biotech companies worldwide to advance basic life sciences research and facilitate drug discovery and development. The subsidiary SignalChem Biotech Inc. is a global leader focused on researching, developing, and producing innovative and high-quality human recombinant cell signaling products.

In addition, subsidiaries SignalChem Diagtech Corp. and SignalChem Plantech Corp. were established in 2018 and 2019 respectively to seize rapid growth opportunities and fully utilize its deep knowledge and expertise in protein engineering, becoming global leaders. While SignalChem Diagtech Corp. concentrates on the development, manufacturing, sales, and technical services of IVD products including CRISPR enzymes and detection systems, and SignalChem Plantech Corp. focuses on the biosynthesis of recombinant proteins and secondary metabolites in green plants.

“We have a group of scientists with extraordinary expertise and experience in protein engineering and drug discovery working cohesively to provide the best products and services to customers around the world to maximize the efficiency of its drug discovery efforts,” says Dr. Zaihui Zhang, CSO, vice president R&D at SignalChem Biotech Inc.

SignalChem’s product portfolio and drug discovery programs are SOMETHING on protein kinases, proteins at the nexus of signaling networks that connect and regulate all cellular processes. In effect, dysregulation of kinases due to over-expression/activation or mutation is often linked to disease onset and progression. Due to their essential role, kinases have spurred a considerable effort toward kinase-targeting drugs. It started its drug discovery and development division in 2012, focusing on developing novel small-molecule kinase inhibitors to treat human diseases with unmet medical needs.

Leveraging its expertise in developing kinase-focused cell signaling products and delivering discovery services for academia and the pharmaceutical industry, SignalChem has positioned itself at the forefront of kinase inhibitor drug discovery. It has developed the most comprehensive kinase catalog products to support research and drug development. Its advantages include, but are not limited to, the largest and ever-growing repertoire of active and mutant kinases, optimized activity-based assays on multiple assay platforms, broad interactions, and partnerships with leading pharmaceutical companies.

Using its kinome-wide screening platform Kinome Search Engine, a powerful target discovery engine, SignalChem has made designer-crafted kinase drug development a reality. This powerful platform has already yielded a robust candidate pipeline for treating different cancers. One of the leading candidates is SLC-391, a small molecule AXL inhibitor entering Phase 2 clinical studies in early 2023.

Since the COVID-19 outbreak, SignalChem also jumped onto the bandwagon to create and develop new research tools related to the SARS-CoV-2 virus. Leveraging advanced protein bioengineering technology to produce active proteins and AI drug development capability, it has already established expression systems for production of SARS-CoV-2 Spike proteins, RBD fragments, N protein, and other related protein products on a large scale to help detect IgG / IgM in potential patients.

Given the growing popularity of clustered regularly interspaced short palindromic repeats (CRISPRs) and their CRISPR-associated (Cas) proteins constituting the CRISPR-Cas immune system, SignalChem DiagTech Corp. also started building its portfolio of products like Cas9, Cas12, Cas13 and Custom CRISPR Associated Proteins. SignalChem’s extensive experience in recombinant protein technologies has allowed it to stay current with the research landscape, building its portfolio of research products efficiently to support their research and IVD customers.

SignalChem DiagTech Corp. strives to become the world’s most professional IVD raw material supplier and develop at least 300 products. It has established its main R&D and production pillars in Vancouver, Canada, and Suzhou, China. It also concentrates on raw materials for all in-vitro diagnostic assay development, like CRISPR, Clinical Chemistry Enzymes, and Molecular and Immuno Diagnostics. SignalChem’s new IVD branch, as a team with a combined research experience of over 100 years and a prominent name in the Kinase field, will serve as an invaluable additional resource for scientists and researchers worldwide.

It is committed to helping clients in every step of their engagement and supporting them throughout the project’s lifetime. SignalChem also collaborates with leading OEMs that cater to customer needs worldwide. Among more than 4000 direct customers, it has renowned clients like Pfizer, Novartis, and Merck. SignalChem also provides customized products to its customers per their specific needs while assuring quality and timely delivery. This enables it to retain and become suitable partners for its customers.